Feed RLMD
RL

Relmada Therapeutics, Inc. RLMD · NASDAQ

$3.27 -0.61% (-$0.02)

Market cap
$350.9M
Enterprise value
$339.6M
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-30.8%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.45
Free float
77.5%

About the company

Relmada Therapeutics, Inc. (RLMD) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system disorders and other neurologically focused health conditions. Their research and development programs are aimed at discovering and developing new drug therapies for mood disorders, pain, and other neurological diseases. Among their main products are drugs based on new pharmacological mechanisms, which have the potential to provide new therapeutic options for patients with these health conditions. Relmada Therapeutics, Inc. aims to bring innovative treatment approaches and improve the quality of life for patients suffering from neurological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Sergio Traversa

Employees

17

Headquarters

Coral Gables

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy